Protein Degradation and Inhibitors

SEP 11, 2026 · JOURNAL ARTICLE

Antagonistic peptide-displayed artificial exosome carrying PROTAC for the synergistic lung cancer therapy

Journal of Nanobiotechnology

Preclinical in vivo study in animal models demonstrating a novel nanoparticle-PROTAC combination system; no human clinical data, efficacy compared only to implied controls, and lacks direct comparison to standard therapies.

SEP 10, 2026 · JOURNAL ARTICLE

Global Bibliometric Analysis of Post-Translational Modifications in Oral Squamous Cell Carcinoma

International Dental Journal

A descriptive bibliometric analysis mapping research landscape and trends rather than testing a clinical or mechanistic hypothesis; documents publication patterns and emerging themes without presenting primary experimental or clinical evidence.

SEP 10, 2026 · JOURNAL ARTICLE

Cancer-driver-agnostic targeting of amplified surface proteins identifies MPZL1 for selective CAR-T cell therapy

Nature Communications

This is preclinical target discovery and validation work using in vitro and animal models; it establishes MPZL1 as a candidate CAR-T target but does not present clinical efficacy data or human trials.

SEP 10, 2026 · JOURNAL ARTICLE

Regulatory roles of five key USP family deubiquitinases in cancer: from mechanisms to targeted therapy advances

Frontiers in Pharmacology

A systematic narrative review of mechanistic literature on five deubiquitinases in cancer, proposing therapeutic targeting strategies without reporting clinical trial data or empirical evidence of efficacy.

SEP 9, 2026 · JOURNAL ARTICLE

Ribitoborate Synergism with Histone Deacetylase Inhibitor Romidepsin as a Potential Treatment for Breast Cancer

International Journal of Molecular Sciences

In vitro mechanistic study in a single TNBC cell line suggesting synergy between two agents, lacking any in vivo validation, patient data, or clinical trial evidence to support therapeutic application.

SEP 9, 2026 · JOURNAL ARTICLE

Beyond hypoxia and ccRCC: the expanding universe of VHL novel targets and next-generation therapeutics

Biomarker Research

A narrative review synthesizing preclinical mechanistic evidence on VHL targets and proposing therapeutic modalities, lacking clinical trial data or human evidence to support practice recommendations.

SEP 8, 2026 · JOURNAL ARTICLE

Targeted protein degradation dismantles undruggable targets to reverse immune evasion and therapy resistance in cancer

Frontiers in Immunology

A comprehensive review summarizing molecular principles, clinical progress, and translational strategies for targeted protein degradation in cancer immunotherapy, rather than reporting original experimental data or trial results.

SEP 8, 2026 · JOURNAL ARTICLE

An AI-Assisted Workflow for Rapid Prioritization of FDA-Approved Drugs as HDAC3 Inhibitor Candidates for Drug Repurposing

Biology

This is an exploratory computational study using machine learning to predict HDAC3 inhibition by FDA-approved drugs, without experimental validation or clinical data, raising mechanistic questions rather than answering therapeutic ones.